À Propos de l'Entreprise
- Raison sociale: Bioworkshops
- Pays d'enregistrement: China
- Adresse: No. 5, Dongwang Road,, Suzhou Industrial Park, Suzhou
- Nombre d'employés: 100 - 249
Description:
A full-service CDMO for antibody products, Bioworkshops offers development and cGMP manufacturing of drug substance and final product, including cell line development, process development, analytical methods, formulation, and process characterization/validation, with 13,000 liters of single-use cell culture capacity (200L to 2000L), three aseptic filling lines for vials, lyophilized products and prefilled syringes/cartridges up to 100,000 units per batch, along with product testing and CTD dossier support.
Activités Commerciales
Produits Biopharmaceutiques
Fabricant sous Contrat (CMO)Entreprise en phase de démarrage (start-up)
Classification ATC (Anatomique, Thérapeutique, Chimique)
Fabricant sous Contrat (CMO)Entreprise en phase de démarrage (start-up)
API de Référence (Princeps)
Fabricant sous Contrat (CMO)Entreprise en phase de démarrage (start-up)
Produits/Services Clés
- Produits Biopharmaceutiques: Trastuzumab emtansine, Trastuzumab deruxtecan, Bedinvetmab, Benralizumab, Bevacizumab, Burosumab, Camrelizumab, Canakinumab, Casirivimab, Cetuximab, Cilgavimab, Daratumumab, Denosumab, Disitamab Vedotin, Dostarlimab, Dulaglutide, Dupilumab, Durvalumab, Eculizumab, Emicizumab, Erenumab, Etesevimab, Evolocumab, Faricimab, Fremanezumab, Frunevetmab, Galcanezumab, Guselkumab, Hyaluronidase Recombinant Human, Imdevimab, Lanadelumab, Lecanemab, Lokivetmab, Mepolizumab, Nirsevimab, Nivolumab, Ocrelizumab, Ofatumumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Polatuzumab, Ramucirumab, Ranibizumab, Ravulizumab, Recombinant Zoster Vaccine, Risankizumab, Rituximab, Romiplostim, Romosozumab, Sarilumab, Sotatercept-csrk, Tezepelumab, Theralizumab, Tixagevimab & Cilgavimab, Tocilizumab, Trastuzumab, Ustekinumab, Adalimumab, Anifrolumab, Atezolizumab, Bamlanivimab, Bebtelovimab
- Services Biopharmaceutiques: Cell Line Development, GMP manufacturing for cell culture products
- Classification ATC (Anatomique, Thérapeutique, Chimique): Respiratory Syncytial Virus Vaccine
Nos Produits & Services
Sell · Biopharmaceutical Products
Certifications
Proofs
CPHI & PMEC China 2026
06/2026 – 06/2026
CPHI & PMEC China 2026
Évaluations
(0)
(0)
(0)
(0)
(0)
Commentaires
Filtres :
Trier par :
Aucun commentaire disponible.
Laissez votre note & commentaire